Written by
Şevval T
Şevval T Liv Hospital Content Team
Medically reviewed by

Related Doctors

Spec. MD. Gizem Güvener Liv Hospital Ulus Spec. MD. Gizem Güvener Pediatrics Spec. MD. Osman Karlı Liv Hospital Ulus Spec. MD. Osman Karlı Pediatrics Spec. MD. Tamer Ünver Liv Hospital Ulus Spec. MD. Tamer Ünver Neonatal Intensive Care Unit (NICU) Assoc. Prof. MD. Adem Dursun Liv Hospital Vadistanbul Assoc. Prof. MD. Adem Dursun Pediatrics Psyc. Selenay Yücel Keleş Liv Hospital Vadistanbul Psyc. Selenay Yücel Keleş Pediatric Psychology Spec. MD.  Fatih Aydın Liv Hospital Vadistanbul Spec. MD. Fatih Aydın Pediatrics Spec. MD. Dicle Çelik Liv Hospital Vadistanbul Spec. MD. Dicle Çelik Pediatrics Spec. MD. Elif Erdem Özcan Liv Hospital Vadistanbul Spec. MD. Elif Erdem Özcan Pediatrics Spec. MD. Hilal Kızıldağ Liv Hospital Vadistanbul Spec. MD. Hilal Kızıldağ Pediatrics Spec. MD. Mehmet Kılıç Liv Hospital Vadistanbul Spec. MD. Mehmet Kılıç Pediatrics Spec. MD. Ozan Uzunhan Liv Hospital Vadistanbul Spec. MD. Ozan Uzunhan Neonatology Spec. MD. Selami Bayrakdar Liv Hospital Vadistanbul Spec. MD. Selami Bayrakdar Pediatrics Spec. MD. Semra Akkuş Akman Liv Hospital Vadistanbul Spec. MD. Semra Akkuş Akman Pediatrics Asst. Prof. MD. Doruk Gül Liv Hospital Bahçeşehir Asst. Prof. MD. Doruk Gül Pediatric Health and Diseases Prof. MD. Murat Sütçü Liv Hospital Bahçeşehir Prof. MD. Murat Sütçü Pediatric Health and Diseases Prof. MD. Nihat Demir Liv Hospital Bahçeşehir Prof. MD. Nihat Demir Pediatrics Psyc. (Psychologist) Buse Yağmur Liv Hospital Bahçeşehir Psyc. (Psychologist) Buse Yağmur Pediatric Psychology Spec. MD. Cansu Muluk Liv Hospital Bahçeşehir Spec. MD. Cansu Muluk Pediatrics Spec. MD. Dilek Hatipoğlu Liv Hospital Bahçeşehir Spec. MD. Dilek Hatipoğlu Pediatric Health and Diseases Spec. MD. Duygu Amine Garavi Liv Hospital Bahçeşehir Spec. MD. Duygu Amine Garavi Pediatrics Spec. MD. Fatih Kaya Liv Hospital Bahçeşehir Spec. MD. Fatih Kaya Pediatric Health and Diseases Spec. MD. Günel Nüsretzade Elmar Liv Hospital Bahçeşehir Spec. MD. Günel Nüsretzade Elmar Pediatrics Spec. MD. Mey Talip Liv Hospital Bahçeşehir Spec. MD. Mey Talip Pediatric Intensive Care Spec. MD. Negın Nahanmoghaddam Liv Hospital Bahçeşehir Spec. MD. Negın Nahanmoghaddam Pediatrics Spec. MD. Nushaba Abdullayeva Liv Hospital Bahçeşehir Spec. MD. Nushaba Abdullayeva Pediatric Health and Diseases Spec. MD. Refika İlbakan Hanımeli Liv Hospital Bahçeşehir Spec. MD. Refika İlbakan Hanımeli Pediatrics Spec. MD. Selman Alazab Liv Hospital Bahçeşehir Spec. MD. Selman Alazab Pediatrics Spec. MD. Özden Durmuş Gönültaş Liv Hospital Bahçeşehir Spec. MD. Özden Durmuş Gönültaş Pediatrics Spec. Md. Öznur Ceylan Liv Hospital Bahçeşehir Spec. Md. Öznur Ceylan Pediatric Health and Diseases Assoc. Prof. MD. Aslan Yılmaz Liv Hospital Topkapı Assoc. Prof. MD. Aslan Yılmaz Neonatology Prof. MD. Alpay Çakmak Liv Hospital Topkapı Prof. MD. Alpay Çakmak Pediatrics Spec. MD. Demet Deniz Bilgin Liv Hospital Topkapı Spec. MD. Demet Deniz Bilgin Pediatrics Spec. MD. Nesrin Köseoğlu Liv Hospital Topkapı Spec. MD. Nesrin Köseoğlu Pediatric and Adolescent Psychiatry Spec. MD. Seçil Sözen Liv Hospital Topkapı Spec. MD. Seçil Sözen Pediatrics Spec. MD. Özge Akça Liv Hospital Topkapı Spec. MD. Özge Akça Pediatrics Spec. MD. Şeyma Öz Liv Hospital Topkapı Spec. MD. Şeyma Öz Pediatrics Asst. Prof. MD. Pakize Elif Alkış Liv Hospital Ankara Asst. Prof. MD. Pakize Elif Alkış Pediatrics Prof. MD. Musa Kazım Çağlar Liv Hospital Ankara Prof. MD. Musa Kazım Çağlar Pediatrics Prof. MD. İbrahim Hakan Bucak Liv Hospital Ankara Prof. MD. İbrahim Hakan Bucak Pediatrics Prof.MD. Sevgi Başkan Liv Hospital Ankara Prof.MD. Sevgi Başkan Pediatrics Spec. MD. Büşra Süzen Celbek Liv Hospital Ankara Spec. MD. Büşra Süzen Celbek Pediatrics Spec. MD. Galip Erdem Liv Hospital Ankara Spec. MD. Galip Erdem Pediatrics Spec. MD. Hafsa Uçur Liv Hospital Ankara Spec. MD. Hafsa Uçur Pediatric Health and Diseases Spec. MD. Hidayet Katipoğlu Liv Hospital Ankara Spec. MD. Hidayet Katipoğlu Pediatric Health and Diseases Spec. MD. Hüsniye Altan Liv Hospital Ankara Spec. MD. Hüsniye Altan Pediatrics Spec. MD. Mehmet Turfanda Liv Hospital Ankara Spec. MD. Mehmet Turfanda Pediatric Health and Diseases Spec. MD. Mustafa Yücel Kızıltan Liv Hospital Ankara Spec. MD. Mustafa Yücel Kızıltan Pediatrics Spec. MD.  Seral Navdar Liv Hospital Gaziantep Spec. MD. Seral Navdar Pediatric Health and Diseases Spec. MD. Gül Balyemez Liv Hospital Gaziantep Spec. MD. Gül Balyemez Pediatric Health and Diseases Spec. MD. Hasan Avşar Liv Hospital Gaziantep Spec. MD. Hasan Avşar Neonatology Spec. MD. Mert Çakır Liv Hospital Gaziantep Spec. MD. Mert Çakır Pediatrics Spec. MD. Saltuk Buğra Böke Liv Hospital Gaziantep Spec. MD. Saltuk Buğra Böke Pediatric Health and Diseases Spec. MD. Özlem Karaoğlu Liv Hospital Gaziantep Spec. MD. Özlem Karaoğlu Pediatric Health and Diseases Spec. MD. İsmail Ersan Can Liv Hospital Gaziantep Spec. MD. İsmail Ersan Can Pediatric Health and Diseases Spec. MD. Şekibe Zehra Doğan Liv Hospital Gaziantep Spec. MD. Şekibe Zehra Doğan Pediatric Health and Diseases Spec. MD. Gülsenem Sarı Aracı Liv Hospital Samsun Spec. MD. Gülsenem Sarı Aracı Pediatric Health and Diseases Spec. MD. Nazlı Karakullukcu Çebi Liv Hospital Samsun Spec. MD. Nazlı Karakullukcu Çebi Pediatrics Spec. MD. Nezih Akgün Liv Hospital Samsun Spec. MD. Nezih Akgün Pediatric Health and Diseases Spec. MD. Pelin Aytaç Uras Liv Hospital Samsun Spec. MD. Pelin Aytaç Uras Pediatrics MD. VEFA İSAYEVA Liv Bona Dea Hospital Bakü MD. VEFA İSAYEVA Pediatric Health and Diseases Spec. MD.  Elnur Hüseynov Liv Bona Dea Hospital Bakü Spec. MD. Elnur Hüseynov Pediatrics Spec. MD. INARE ELDAROVA Liv Bona Dea Hospital Bakü Spec. MD. INARE ELDAROVA Pediatrics Spec. MD. SADİQ İSMAYILOV Liv Bona Dea Hospital Bakü Spec. MD. SADİQ İSMAYILOV Pediatric Health and Diseases MD. Dr. Elnur Hüseynov MD. Dr. Elnur Hüseynov Pediatrics Spec. MD. Doğa Sevinçok Spec. MD. Doğa Sevinçok Pediatric and Adolescent Psychiatry Spec. MD. Sadık İsmayılov Pediatrics Assoc. Prof. MD. Muhammet Ali Varkal Liv Hospital Ulus + Liv Hospital Topkapı Assoc. Prof. MD. Muhammet Ali Varkal Pediatrics Spec. MD. Melike Akar Liv Hospital Bahçeşehir + Liv Hospital Topkapı Spec. MD. Melike Akar Pediatrics
...
Views
Read Time
...
views
Read Time
Childhood Leukemia Survival: 7 Essential Facts for Parents
Childhood Leukemia Survival: 7 Essential Facts for Parents 4

Medical treatments have greatly improved for kids with leukemia. Thanks to top care from specialized centers, the five-year survival rate is now over 85 percent for many.

It’s key for parents to know the latest survival statistics when dealing with this diagnosis. Different leukemia types have different survival chances. Knowing this helps families make informed choices.

Key Takeaways

  • The overall five-year survival rate for childhood leukemia has surpassed 85 percent.
  • Different types of leukemia have varying survival rates.
  • Advances in medical treatment have improved the outlook for children with leukemia.
  • Specialized care centers play a critical role in boosting survival rates.
  • Understanding current survival statistics is vital for making informed decisions.

The Remarkable Progress in Childhood Leukemia Survival

Childhood Leukemia Survival: 7 Essential Facts for Parents
Childhood Leukemia Survival: 7 Essential Facts for Parents 5

Childhood leukemia used to be almost always fatal. But now, thanks to medical research and new treatments, survival rates have greatly improved. This shows how far we’ve come in understanding and treating this disease.

Historical Perspective on Childhood Leukemia Treatment

In the old days, leukemia was a death sentence for kids. Before the 1970s, only about 10% of kids with leukemia lived five years after being diagnosed. Back then, treatments were few, and the disease was a mystery.

Chemotherapy came along in the mid-1900s and changed everything. It was the start of a new chapter in fighting leukemia. Many studies and trials have led to better, safer treatments.

Key Milestones in Improving Survival Rates

There have been a few big moments that have helped kids with leukemia live longer. These include:

  • The creation of combo chemotherapy regimens
  • Advances in care, like better infection management and blood transfusions
  • The start of targeted and immunotherapies
  • Better ways to figure out who needs what treatment

Current Overall Survival Statistics

Today, more kids with leukemia are living longer. About 85% of kids in North America and Europe with leukemia survive at least five years after diagnosis. This is thanks to all the hard work of researchers, doctors, and families.

The progress in treating childhood leukemia gives hope to families dealing with this disease. With ongoing research and medical advancements, we can expect even better survival rates and quality of life for survivors.

Understanding Childhood Leukemia: Types and Differences

Childhood Leukemia Survival: 7 Essential Facts for Parents
Childhood Leukemia Survival: 7 Essential Facts for Parents 6

Childhood leukemia is not just one disease. It’s a group of cancers that affect the blood and bone marrow. The two main types are Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). Each has its own characteristics and treatment methods.

Acute Lymphoblastic Leukemia (ALL)

ALL is the most common childhood leukemia, making up 75-80% of cases. It’s caused by the fast growth of immature lymphocytes, a type of white blood cell. Today, the five-year survival rate for ALL is over 90% in many cases. Treatment for ALL includes chemotherapy and sometimes maintenance therapy to prevent relapse.

A leading leukemia researcher says, “Risk-stratified therapy for ALL has been a big step forward. It lets us give high-risk patients more treatment while keeping lower-risk patients safe.” This has helped improve survival rates for children with ALL.

Acute Myeloid Leukemia (AML)

AML is harder to treat and makes up 20-25% of childhood leukemia cases. It’s caused by the fast growth of abnormal myeloid cells in the bone marrow. The prognosis for AML depends on the child’s age, genetic abnormalities, and how well they respond to treatment. Treatment for AML includes intensive chemotherapy and sometimes a stem cell transplant.

A study in the Journal of Clinical Oncology found that “new ways to understand AML have led to finding new treatments and better ways to predict outcomes.” This has helped make treatments more personalized and effective for children with AML.

Other Less Common Types

There are other, less common types of leukemia, like Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid Leukemia (CML). These are rare in children. They have different characteristics and treatments from ALL and AML. For example, CLL is more common in adults, and when it happens in children, it needs a different treatment plan.

  • Chronic Lymphocytic Leukemia (CLL): Rare in children, CLL involves the gradual accumulation of mature lymphocytes.
  • Chronic Myeloid Leukemia (CML): CML is characterized by the uncontrolled growth of myeloid cells and is more common in adults.
  • Juvenile Myelomonocytic Leukemia (JMML): A rare type of leukemia that occurs in young children, often associated with genetic mutations.

Knowing about these different types of leukemia is key to creating effective treatment plans. As research keeps improving, the outlook for children with leukemia is getting better.

Acute Lymphoblastic Leukemia (ALL): The Most Common and Most Treatable

Childhood Acute Lymphoblastic Leukemia (ALL) is now one of the most treatable cancers. This is thanks to new medical research and better treatment plans. ALL is a cancer that affects the blood and bone marrow, causing too many immature white blood cells.

Thanks to years of research and clinical trials, we now have better ways to treat ALL. This has greatly improved the chances of survival for children with this disease.

Current Five-Year Survival Rates for ALL

The five-year survival rate for children with ALL is about 90 percent. This shows how far we’ve come in treating this cancer. The survival rate means the percentage of kids who live at least five years after being diagnosed.

B-Cell vs. T-Cell ALL Survival Differences

ALL is divided into B-cell and T-cell types, each with different survival chances. B-cell ALL makes up about 85% of cases and has a high cure rate, with survival rates over 90% in many studies. T-cell ALL, once seen as having a poorer prognosis, has also seen survival rates improve with modern treatments.

Knowing whether a child has B-cell or T-cell ALL is important. It helps doctors decide on the best treatment. Children with B-cell ALL usually get less intense chemotherapy than those with T-cell ALL, who need more aggressive treatment.

Treatment Protocols That Have Improved Outcomes

Several treatment plans have helped improve survival rates in childhood ALL. These include:

  • Risk stratification: Treatment is tailored based on the risk of relapse.
  • Intensification of chemotherapy: Higher doses of chemotherapy for high-risk patients.
  • Targeted therapy: Use of drugs that target specific cancer cells.
  • Supportive care: Advances in managing side effects and complications.

The following table summarizes the key factors influencing survival rates in childhood ALL:

FactorImpact on Survival
B-cell ALLHigher survival rates (>90%)
T-cell ALLLower survival rates compared to B-cell ALL, but improving
Risk StratificationTailors treatment to risk, improving outcomes
Modern ChemotherapyMore effective and targeted, reducing toxicity

Thanks to these advancements, ALL is now one of the most curable childhood cancers. Ongoing research and better treatment plans will likely continue to improve survival rates and quality of life for children with ALL.

Acute Myeloid Leukemia (AML): Challenging But Improving Outcomes

Children with AML now have better chances of survival thanks to new treatments. AML is a blood and bone marrow cancer. It grows fast and blocks normal blood cell production.

Current Five-Year Survival Rates for AML

There’s been a big leap in treating childhood AML. Now, over 65 percent of kids survive five years after diagnosis. This gain is thanks to better chemotherapy and care.

Studies show that survival rates for AML in kids have gone up over the years.

YearFive-Year Survival Rate
1990s40%
2000s55%
2020s65%

Recent Advances in AML Treatment

New treatments for AML have been introduced. These include stronger chemotherapy and stem cell transplants. For more info on childhood AML, check outthis resource.

Targeted therapies and better care have also helped. These steps have made AML treatment more effective.

Factors That Influence AML Prognosis

Several things affect how well a child with AML will do. These include genetic traits, how well they respond to treatment, and MRD levels. Kids with certain genes may face different challenges.

  • Genetic abnormalities
  • Response to initial treatment
  • Presence of MRD

Childhood Leukemia Survival Rates by Age Group

Childhood leukemia survival rates change with age. Infants, young children, and teens face different challenges. Knowing these differences helps parents and doctors make better treatment choices.

Infants (Under 1 Year)

Infants with leukemia have a tough time. Infant leukemia survival rates are lower than for older kids. This is because the disease is very aggressive in babies, and treating them is hard.

Studies show that babies under 1 with ALL have a lower survival rate. This is often because of certain genetic problems, like the MLL gene rearrangement, which is more common in infant leukemia.

Young Children (Ages 1-9)

Children aged 1 to 9 have seen big improvements in leukemia survival. This age group usually has a better chance of beating the disease, thanks to ALL.

The childhood leukemia survival rates by age show that kids in this age group do better. They can handle chemotherapy better and are less likely to have high-risk genetic features.

Adolescents (Ages 10-19)

Adolescents with leukemia face unique challenges. While treatments have gotten better, they are at higher risk for side effects and may not respond as well to therapy.

Research shows that teens with ALL have a slightly lower survival rate than younger kids. But their overall chances of survival are good. The leukemia in babies survival rate is different from that of teens, showing the need for age-specific treatments.

Understanding the differences in childhood leukemia survival rates by age helps doctors and families make better choices. This way, they can navigate the complexities of leukemia treatment more effectively.

Genetic and Biological Factors Affecting Childhood Leukemia Survival

Genetic and biological factors are key to how well kids with leukemia do. These factors can change how a child reacts to treatment and their chances of getting better.

Chromosomal Abnormalities and Their Impact

Chromosomal abnormalities are a big deal in childhood leukemia. Some, like extra chromosome 21 or certain translocations, can make leukemia cells act differently. For example, kids with Down syndrome might do better in treatment because their cells are more sensitive to drugs.

Translocations, like the ETV6-RUNX1 fusion, are common in B-cell ALL and usually mean a good outlook. But some, like the MLL gene rearrangement, are linked to a worse prognosis.

Minimal Residual Disease (MRD) Status

Minimal Residual Disease (MRD) is when leukemia cells stay in the body after treatment. MRD status is a strong sign of how likely a child is to relapse and survive. Kids with low or undetectable MRD usually have a better chance, while those with high MRD levels face a higher risk.

By checking MRD with flow cytometry or PCR, doctors can see how well treatment is working. This helps tailor treatment to each child, leading to better results.

Other Biological Markers

Other biological markers also play a role in survival rates for kids with leukemia. These include genetic mutations, like those in the TP53 or IKZF1 genes, and certain proteins in leukemia cells.

For instance, some surface antigens help doctors classify leukemia types and decide on treatments. Knowing these markers is key to creating targeted therapies and better patient care.

Special Considerations for Infant Leukemia

Infants with leukemia face unique challenges that need special treatments. Leukemia in babies, like Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), is different from leukemia in older kids.

Why Infant Leukemia Has Lower Survival Rates

Infant leukemia often has lower survival rates than in older kids. This is due to several reasons, including mixed lineage leukemia (MLL) gene rearrangements. These are more common in infants and often mean a worse prognosis.

Infants’ young immune systems and fast disease progression make treatment harder. Their developing organs are also more at risk from chemotherapy’s side effects. This makes it tough to treat without harming them long-term.

Specialized Treatment Protocols for Infants

Researchers and doctors are working on special treatments for infant leukemia. These aim to boost survival rates while reducing harm from treatment.

Treatment for infant leukemia might include chemotherapy, targeted therapy, and sometimes stem cell transplants. The treatment plan is made just for the infant, based on their risk level. This is decided by things like MLL gene rearrangements and how well they respond to treatment.

Treatment ComponentDescriptionBenefit
ChemotherapyIntensive multi-agent chemotherapy regimensEffective in achieving remission
Targeted TherapyDrugs targeting specific molecular abnormalitiesReduces toxicity and improves efficacy
Stem Cell TransplantationReplaces the infant’s bone marrow with healthy cellsOffers a potentially curative option for high-risk cases

Recent Improvements in Infant Leukemia Outcomes

In recent years, there have been big steps forward in treating infant leukemia. New, less harmful treatments have helped increase survival rates.

Studies are ongoing to make treatments even better. They focus on tailoring therapy for each infant’s risk level. New drugs and targeted therapies are being tested to improve outcomes for babies with leukemia.

Long-Term Survival and Quality of Life After Childhood Leukemia

Medical treatments for childhood leukemia have gotten better. Now, we focus on long-term survival and quality of life. Survivors face many challenges after treatment, making ongoing care key.

Late Effects of Treatment

Childhood leukemia survivors may face late effects of treatment. These can include organ damage, growth issues, and a higher risk of secondary cancers. For example, some chemotherapy and radiation can harm the heart later in life. Regular follow-up care is essential to monitor and manage these effects.

Follow-Up Care and Monitoring

Follow-up care for survivors includes regular check-ups and monitoring for late effects. A detailed care plan helps survivors deal with long-term challenges. This may include screenings for secondary cancers, heart checks, and overall health assessments.

Psychosocial Outcomes for Survivors

The psychosocial outcomes for childhood leukemia survivors vary. While many lead healthy, fulfilling lives, others face anxiety, depression, or social and emotional challenges. Access to psychosocial support services, like counseling and support groups, is vital for coping.

What Parents Should Know About Relapse and Second-Line Treatments

Childhood leukemia relapse is a complex issue that parents need to understand. It happens when leukemia comes back after treatment ends. Knowing the risks, signs, and treatment options is key for parents.

Relapse Rates and Survival After Relapse

Relapse rates depend on the leukemia type and initial treatment response. For example, kids with Acute Lymphoblastic Leukemia (ALL) face different outcomes based on when and where the relapse happens.

  • Early Relapse: Relapse within a year of diagnosis usually has a poorer prognosis.
  • Late Relapse: Relapse after a longer time may have better outcomes.

Thanks to new treatments, survival after relapse has improved. This includes new chemotherapy and targeted therapies.

New and Emerging Therapies for Relapsed Leukemia

The treatment for relapsed leukemia is changing. New and emerging therapies are showing promise.

  1. Targeted Therapies: Drugs that target specific genetic mutations or proteins in leukemia cells.
  2. Immunotherapies: Treatments that use the immune system to fight leukemia, like CAR-T cell therapy.
  3. Clinical Trials: Ongoing studies looking into new drugs and treatment combinations.

These therapies offer hope for better outcomes in children with relapsed leukemia.

Stem Cell Transplantation Outcomes

Stem cell transplantation is a treatment for some children with relapsed leukemia. It replaces the diseased bone marrow with healthy stem cells.

“Stem cell transplantation can be a curative option for patients with high-risk or relapsed leukemia, giving them a chance for long-term survival.”

-Hematology experts highlight.

Outcomes after stem cell transplantation have gotten better. This is thanks to better donor matching, reduced-intensity conditioning regimens, and advances in post-transplant care.

Conclusion: Hope and Perspective for Parents Facing Childhood Leukemia

Getting a diagnosis of childhood leukemia is tough for families. But thanks to new treatments, many kids are now surviving. This gives hope to parents of kids with leukemia.

The path to recovery is long and hard. But knowing about leukemia types, treatments, and survival chances helps parents. Thanks to ongoing research, the outlook for families with leukemia is getting better.

As treatments get better, it’s key for parents to stay updated. Working with doctors helps ensure their child gets the best care. This way, families can face leukemia’s challenges with hope and confidence for a brighter future.

FAQ

What is the overall survival rate for childhood leukemia?

The five-year survival rate for childhood leukemia is over 85 percent. This shows a big improvement in treatment.

How do survival rates differ between acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)?

ALL has a better five-year survival rate than AML. This is because of new treatments for ALL.

What are the survival rates for B-cell and T-cell ALL?

B-cell ALL usually has a higher survival rate than T-cell ALL. But, both have seen better outcomes thanks to new treatments.

How does age affect childhood leukemia survival rates?

Infants under one year have lower survival rates. Young children aged 1-9 have the highest rates. Adolescents face challenges that can affect their survival.

What genetic and biological factors influence childhood leukemia survival?

Chromosomal abnormalities and minimal residual disease (MRD) status are key. They help predict prognosis and guide treatment.

Why does infant leukemia have a lower survival rate?

Infant leukemia often has high-risk genetic features. It needs special treatments, leading to lower survival rates.

What are the late effects of childhood leukemia treatment?

Survivors might face organ damage, secondary cancers, and psychosocial challenges. This shows the need for ongoing care.

What are the chances of survival after a leukemia relapse?

Survival after relapse depends on leukemia type, timing, and treatment response. New therapies are helping.

How effective is stem cell transplantation in treating childhood leukemia?

Stem cell transplantation is effective for some relapsed or high-risk leukemia cases. It offers a chance of a cure for some patients.

Is childhood leukemia curable?

Yes, many children with leukemia are cured. Advances in treatment are improving cure rates.

What is the cure rate for childhood acute lymphoblastic leukemia (ALL)?

The cure rate for childhood ALL is about 90 percent or higher for some subtypes. It’s one of the most treatable cancers in kids.

What is the prognosis for childhood acute myeloid leukemia (AML)?

AML’s prognosis depends on genetic characteristics and treatment response. But, survival rates are improving with new therapies.

How do childhood leukemia survival rates compare across different studies?

Survival rates might vary slightly between studies. This is due to different populations, treatments, and follow-up periods. But, overall, outcomes are getting better.

References

  1. Buechner, J., Zwaan, C. M., Pabst, T., & Creutzig, U. (2023). Pediatric Acute Myeloid Leukemia — Past, Present, and Future. Frontiers in Pediatrics, 11, Article 8837075. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837075/
  2. National Cancer Institute. (2025, January). Childhood Acute Myeloid Leukemia Treatment (PDQ®). https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Spec. MD. Gizem Güvener Liv Hospital Ulus Spec. MD. Gizem Güvener Pediatrics Spec. MD. Osman Karlı Liv Hospital Ulus Spec. MD. Osman Karlı Pediatrics Spec. MD. Tamer Ünver Liv Hospital Ulus Spec. MD. Tamer Ünver Neonatal Intensive Care Unit (NICU) Assoc. Prof. MD. Adem Dursun Liv Hospital Vadistanbul Assoc. Prof. MD. Adem Dursun Pediatrics Psyc. Selenay Yücel Keleş Liv Hospital Vadistanbul Psyc. Selenay Yücel Keleş Pediatric Psychology Spec. MD.  Fatih Aydın Liv Hospital Vadistanbul Spec. MD. Fatih Aydın Pediatrics Spec. MD. Dicle Çelik Liv Hospital Vadistanbul Spec. MD. Dicle Çelik Pediatrics Spec. MD. Elif Erdem Özcan Liv Hospital Vadistanbul Spec. MD. Elif Erdem Özcan Pediatrics Spec. MD. Hilal Kızıldağ Liv Hospital Vadistanbul Spec. MD. Hilal Kızıldağ Pediatrics Spec. MD. Mehmet Kılıç Liv Hospital Vadistanbul Spec. MD. Mehmet Kılıç Pediatrics Spec. MD. Ozan Uzunhan Liv Hospital Vadistanbul Spec. MD. Ozan Uzunhan Neonatology Spec. MD. Selami Bayrakdar Liv Hospital Vadistanbul Spec. MD. Selami Bayrakdar Pediatrics Spec. MD. Semra Akkuş Akman Liv Hospital Vadistanbul Spec. MD. Semra Akkuş Akman Pediatrics Asst. Prof. MD. Doruk Gül Liv Hospital Bahçeşehir Asst. Prof. MD. Doruk Gül Pediatric Health and Diseases Prof. MD. Murat Sütçü Liv Hospital Bahçeşehir Prof. MD. Murat Sütçü Pediatric Health and Diseases Prof. MD. Nihat Demir Liv Hospital Bahçeşehir Prof. MD. Nihat Demir Pediatrics Psyc. (Psychologist) Buse Yağmur Liv Hospital Bahçeşehir Psyc. (Psychologist) Buse Yağmur Pediatric Psychology Spec. MD. Cansu Muluk Liv Hospital Bahçeşehir Spec. MD. Cansu Muluk Pediatrics Spec. MD. Dilek Hatipoğlu Liv Hospital Bahçeşehir Spec. MD. Dilek Hatipoğlu Pediatric Health and Diseases Spec. MD. Duygu Amine Garavi Liv Hospital Bahçeşehir Spec. MD. Duygu Amine Garavi Pediatrics Spec. MD. Fatih Kaya Liv Hospital Bahçeşehir Spec. MD. Fatih Kaya Pediatric Health and Diseases Spec. MD. Günel Nüsretzade Elmar Liv Hospital Bahçeşehir Spec. MD. Günel Nüsretzade Elmar Pediatrics Spec. MD. Mey Talip Liv Hospital Bahçeşehir Spec. MD. Mey Talip Pediatric Intensive Care Spec. MD. Negın Nahanmoghaddam Liv Hospital Bahçeşehir Spec. MD. Negın Nahanmoghaddam Pediatrics Spec. MD. Nushaba Abdullayeva Liv Hospital Bahçeşehir Spec. MD. Nushaba Abdullayeva Pediatric Health and Diseases Spec. MD. Refika İlbakan Hanımeli Liv Hospital Bahçeşehir Spec. MD. Refika İlbakan Hanımeli Pediatrics Spec. MD. Selman Alazab Liv Hospital Bahçeşehir Spec. MD. Selman Alazab Pediatrics Spec. MD. Özden Durmuş Gönültaş Liv Hospital Bahçeşehir Spec. MD. Özden Durmuş Gönültaş Pediatrics Spec. Md. Öznur Ceylan Liv Hospital Bahçeşehir Spec. Md. Öznur Ceylan Pediatric Health and Diseases Assoc. Prof. MD. Aslan Yılmaz Liv Hospital Topkapı Assoc. Prof. MD. Aslan Yılmaz Neonatology Prof. MD. Alpay Çakmak Liv Hospital Topkapı Prof. MD. Alpay Çakmak Pediatrics Spec. MD. Demet Deniz Bilgin Liv Hospital Topkapı Spec. MD. Demet Deniz Bilgin Pediatrics Spec. MD. Nesrin Köseoğlu Liv Hospital Topkapı Spec. MD. Nesrin Köseoğlu Pediatric and Adolescent Psychiatry Spec. MD. Seçil Sözen Liv Hospital Topkapı Spec. MD. Seçil Sözen Pediatrics Spec. MD. Özge Akça Liv Hospital Topkapı Spec. MD. Özge Akça Pediatrics Spec. MD. Şeyma Öz Liv Hospital Topkapı Spec. MD. Şeyma Öz Pediatrics Asst. Prof. MD. Pakize Elif Alkış Liv Hospital Ankara Asst. Prof. MD. Pakize Elif Alkış Pediatrics Prof. MD. Musa Kazım Çağlar Liv Hospital Ankara Prof. MD. Musa Kazım Çağlar Pediatrics Prof. MD. İbrahim Hakan Bucak Liv Hospital Ankara Prof. MD. İbrahim Hakan Bucak Pediatrics Prof.MD. Sevgi Başkan Liv Hospital Ankara Prof.MD. Sevgi Başkan Pediatrics Spec. MD. Büşra Süzen Celbek Liv Hospital Ankara Spec. MD. Büşra Süzen Celbek Pediatrics Spec. MD. Galip Erdem Liv Hospital Ankara Spec. MD. Galip Erdem Pediatrics Spec. MD. Hafsa Uçur Liv Hospital Ankara Spec. MD. Hafsa Uçur Pediatric Health and Diseases Spec. MD. Hidayet Katipoğlu Liv Hospital Ankara Spec. MD. Hidayet Katipoğlu Pediatric Health and Diseases Spec. MD. Hüsniye Altan Liv Hospital Ankara Spec. MD. Hüsniye Altan Pediatrics Spec. MD. Mehmet Turfanda Liv Hospital Ankara Spec. MD. Mehmet Turfanda Pediatric Health and Diseases Spec. MD. Mustafa Yücel Kızıltan Liv Hospital Ankara Spec. MD. Mustafa Yücel Kızıltan Pediatrics Spec. MD.  Seral Navdar Liv Hospital Gaziantep Spec. MD. Seral Navdar Pediatric Health and Diseases Spec. MD. Gül Balyemez Liv Hospital Gaziantep Spec. MD. Gül Balyemez Pediatric Health and Diseases Spec. MD. Hasan Avşar Liv Hospital Gaziantep Spec. MD. Hasan Avşar Neonatology Spec. MD. Mert Çakır Liv Hospital Gaziantep Spec. MD. Mert Çakır Pediatrics Spec. MD. Saltuk Buğra Böke Liv Hospital Gaziantep Spec. MD. Saltuk Buğra Böke Pediatric Health and Diseases Spec. MD. Özlem Karaoğlu Liv Hospital Gaziantep Spec. MD. Özlem Karaoğlu Pediatric Health and Diseases Spec. MD. İsmail Ersan Can Liv Hospital Gaziantep Spec. MD. İsmail Ersan Can Pediatric Health and Diseases Spec. MD. Şekibe Zehra Doğan Liv Hospital Gaziantep Spec. MD. Şekibe Zehra Doğan Pediatric Health and Diseases Spec. MD. Gülsenem Sarı Aracı Liv Hospital Samsun Spec. MD. Gülsenem Sarı Aracı Pediatric Health and Diseases Spec. MD. Nazlı Karakullukcu Çebi Liv Hospital Samsun Spec. MD. Nazlı Karakullukcu Çebi Pediatrics Spec. MD. Nezih Akgün Liv Hospital Samsun Spec. MD. Nezih Akgün Pediatric Health and Diseases Spec. MD. Pelin Aytaç Uras Liv Hospital Samsun Spec. MD. Pelin Aytaç Uras Pediatrics MD. VEFA İSAYEVA Liv Bona Dea Hospital Bakü MD. VEFA İSAYEVA Pediatric Health and Diseases Spec. MD.  Elnur Hüseynov Liv Bona Dea Hospital Bakü Spec. MD. Elnur Hüseynov Pediatrics Spec. MD. INARE ELDAROVA Liv Bona Dea Hospital Bakü Spec. MD. INARE ELDAROVA Pediatrics Spec. MD. SADİQ İSMAYILOV Liv Bona Dea Hospital Bakü Spec. MD. SADİQ İSMAYILOV Pediatric Health and Diseases MD. Dr. Elnur Hüseynov MD. Dr. Elnur Hüseynov Pediatrics Spec. MD. Doğa Sevinçok Spec. MD. Doğa Sevinçok Pediatric and Adolescent Psychiatry Spec. MD. Sadık İsmayılov Pediatrics Assoc. Prof. MD. Muhammet Ali Varkal Liv Hospital Ulus + Liv Hospital Topkapı Assoc. Prof. MD. Muhammet Ali Varkal Pediatrics Spec. MD. Melike Akar Liv Hospital Bahçeşehir + Liv Hospital Topkapı Spec. MD. Melike Akar Pediatrics
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Muhammet Ali Varkal Pediatrics

Assoc. Prof. MD. Muhammet Ali Varkal

Liv Hospital Ulus
Liv Hospital Topkapı
Spec. MD. Gizem Güvener Pediatrics

Spec. MD. Gizem Güvener

Liv Hospital Ulus
Spec. MD. Osman Karlı Pediatrics

Spec. MD. Osman Karlı

Liv Hospital Ulus
Spec. MD. Tamer Ünver Neonatal Intensive Care Unit (NICU)

Spec. MD. Tamer Ünver

Liv Hospital Ulus
Assoc. Prof. MD. Adem Dursun Pediatrics

Assoc. Prof. MD. Adem Dursun

Liv Hospital Vadistanbul
Psyc. Selenay Yücel Keleş Pediatric Psychology

Psyc. Selenay Yücel Keleş

Liv Hospital Vadistanbul
Spec. MD.  Fatih Aydın Pediatrics

Spec. MD. Fatih Aydın

Liv Hospital Vadistanbul
Spec. MD. Dicle Çelik Pediatrics

Spec. MD. Dicle Çelik

Liv Hospital Vadistanbul
Spec. MD. Elif Erdem Özcan Pediatrics

Spec. MD. Elif Erdem Özcan

Liv Hospital Vadistanbul
Spec. MD. Hilal Kızıldağ Pediatrics

Spec. MD. Hilal Kızıldağ

Liv Hospital Vadistanbul
Spec. MD. Mehmet Kılıç Pediatrics

Spec. MD. Mehmet Kılıç

Liv Hospital Vadistanbul
Spec. MD. Ozan Uzunhan Neonatology

Spec. MD. Ozan Uzunhan

Liv Hospital Vadistanbul
Spec. MD. Selami Bayrakdar Pediatrics

Spec. MD. Selami Bayrakdar

Liv Hospital Vadistanbul
Spec. MD. Semra Akkuş Akman Pediatrics

Spec. MD. Semra Akkuş Akman

Liv Hospital Vadistanbul
Asst. Prof. MD. Doruk Gül Pediatric Health and Diseases

Asst. Prof. MD. Doruk Gül

Liv Hospital Bahçeşehir
Prof. MD. Murat Sütçü Pediatric Health and Diseases

Prof. MD. Murat Sütçü

Liv Hospital Bahçeşehir
Prof. MD. Nihat Demir Pediatrics

Prof. MD. Nihat Demir

Liv Hospital Bahçeşehir
Psyc. (Psychologist) Buse Yağmur Pediatric Psychology

Psyc. (Psychologist) Buse Yağmur

Liv Hospital Bahçeşehir
Spec. MD. Cansu Muluk Pediatrics

Spec. MD. Cansu Muluk

Liv Hospital Bahçeşehir
Spec. MD. Dilek Hatipoğlu Pediatric Health and Diseases

Spec. MD. Dilek Hatipoğlu

Liv Hospital Bahçeşehir
Spec. MD. Duygu Amine Garavi Pediatrics

Spec. MD. Duygu Amine Garavi

Liv Hospital Bahçeşehir
Spec. MD. Fatih Kaya Pediatric Health and Diseases

Spec. MD. Fatih Kaya

Liv Hospital Bahçeşehir
Spec. MD. Günel Nüsretzade Elmar Pediatrics

Spec. MD. Günel Nüsretzade Elmar

Liv Hospital Bahçeşehir
Spec. MD. Melike Akar Pediatrics

Spec. MD. Melike Akar

Liv Hospital Bahçeşehir
Liv Hospital Topkapı
Spec. MD. Mey Talip Pediatric Intensive Care

Spec. MD. Mey Talip

Liv Hospital Bahçeşehir
Spec. MD. Negın Nahanmoghaddam Pediatrics

Spec. MD. Negın Nahanmoghaddam

Liv Hospital Bahçeşehir
Spec. MD. Nushaba Abdullayeva Pediatric Health and Diseases

Spec. MD. Nushaba Abdullayeva

Liv Hospital Bahçeşehir
Spec. MD. Refika İlbakan Hanımeli Pediatrics

Spec. MD. Refika İlbakan Hanımeli

Liv Hospital Bahçeşehir
Spec. MD. Selman Alazab Pediatrics

Spec. MD. Selman Alazab

Liv Hospital Bahçeşehir
Spec. MD. Özden Durmuş Gönültaş Pediatrics

Spec. MD. Özden Durmuş Gönültaş

Liv Hospital Bahçeşehir
Spec. Md. Öznur Ceylan Pediatric Health and Diseases

Spec. Md. Öznur Ceylan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Aslan Yılmaz Neonatology

Assoc. Prof. MD. Aslan Yılmaz

Liv Hospital Topkapı
Prof. MD. Alpay Çakmak Pediatrics

Prof. MD. Alpay Çakmak

Liv Hospital Topkapı
Spec. MD. Demet Deniz Bilgin Pediatrics

Spec. MD. Demet Deniz Bilgin

Liv Hospital Topkapı
Spec. MD. Nesrin Köseoğlu Pediatric and Adolescent Psychiatry

Spec. MD. Nesrin Köseoğlu

Liv Hospital Topkapı
Spec. MD. Seçil Sözen Pediatrics

Spec. MD. Seçil Sözen

Liv Hospital Topkapı
Spec. MD. Özge Akça Pediatrics

Spec. MD. Özge Akça

Liv Hospital Topkapı
Spec. MD. Şeyma Öz Pediatrics

Spec. MD. Şeyma Öz

Liv Hospital Topkapı
Asst. Prof. MD. Pakize Elif Alkış Pediatrics

Asst. Prof. MD. Pakize Elif Alkış

Liv Hospital Ankara
Prof. MD. Musa Kazım Çağlar Pediatrics

Prof. MD. Musa Kazım Çağlar

Liv Hospital Ankara
Prof. MD. İbrahim Hakan Bucak Pediatrics

Prof. MD. İbrahim Hakan Bucak

Liv Hospital Ankara
Prof.MD. Sevgi Başkan Pediatrics

Prof.MD. Sevgi Başkan

Liv Hospital Ankara
Spec. MD. Büşra Süzen Celbek Pediatrics

Spec. MD. Büşra Süzen Celbek

Liv Hospital Ankara
Spec. MD. Galip Erdem Pediatrics

Spec. MD. Galip Erdem

Liv Hospital Ankara
Spec. MD. Hafsa Uçur Pediatric Health and Diseases

Spec. MD. Hafsa Uçur

Liv Hospital Ankara
Spec. MD. Hidayet Katipoğlu Pediatric Health and Diseases

Spec. MD. Hidayet Katipoğlu

Liv Hospital Ankara
Spec. MD. Hüsniye Altan Pediatrics

Spec. MD. Hüsniye Altan

Liv Hospital Ankara
Spec. MD. Mehmet Turfanda Pediatric Health and Diseases

Spec. MD. Mehmet Turfanda

Liv Hospital Ankara
Spec. MD. Mustafa Yücel Kızıltan Pediatrics

Spec. MD. Mustafa Yücel Kızıltan

Liv Hospital Ankara
Spec. MD.  Seral Navdar Pediatric Health and Diseases

Spec. MD. Seral Navdar

Liv Hospital Gaziantep
Spec. MD. Gül Balyemez Pediatric Health and Diseases

Spec. MD. Gül Balyemez

Liv Hospital Gaziantep
Spec. MD. Hasan Avşar Neonatology

Spec. MD. Hasan Avşar

Liv Hospital Gaziantep
Spec. MD. Mert Çakır Pediatrics

Spec. MD. Mert Çakır

Liv Hospital Gaziantep
Spec. MD. Saltuk Buğra Böke Pediatric Health and Diseases

Spec. MD. Saltuk Buğra Böke

Liv Hospital Gaziantep
Spec. MD. Özlem Karaoğlu Pediatric Health and Diseases

Spec. MD. Özlem Karaoğlu

Liv Hospital Gaziantep
Spec. MD. İsmail Ersan Can Pediatric Health and Diseases

Spec. MD. İsmail Ersan Can

Liv Hospital Gaziantep
Spec. MD. Şekibe Zehra Doğan Pediatric Health and Diseases

Spec. MD. Şekibe Zehra Doğan

Liv Hospital Gaziantep
Spec. MD. Gülsenem Sarı Aracı Pediatric Health and Diseases

Spec. MD. Gülsenem Sarı Aracı

Liv Hospital Samsun
Spec. MD. Nazlı Karakullukcu Çebi Pediatrics

Spec. MD. Nazlı Karakullukcu Çebi

Liv Hospital Samsun
Spec. MD. Nezih Akgün Pediatric Health and Diseases

Spec. MD. Nezih Akgün

Liv Hospital Samsun
Spec. MD. Pelin Aytaç Uras Pediatrics

Spec. MD. Pelin Aytaç Uras

Liv Hospital Samsun
MD. VEFA İSAYEVA Pediatric Health and Diseases

MD. VEFA İSAYEVA

Liv Bona Dea Hospital Bakü
Spec. MD.  Elnur Hüseynov Pediatrics

Spec. MD. Elnur Hüseynov

Liv Bona Dea Hospital Bakü
Spec. MD. INARE ELDAROVA Pediatrics

Spec. MD. INARE ELDAROVA

Liv Bona Dea Hospital Bakü
Spec. MD. SADİQ İSMAYILOV Pediatric Health and Diseases

Spec. MD. SADİQ İSMAYILOV

Liv Bona Dea Hospital Bakü
MD. Dr. Elnur Hüseynov Pediatrics

MD. Dr. Elnur Hüseynov

Spec. MD. Doğa Sevinçok Pediatric and Adolescent Psychiatry

Spec. MD. Doğa Sevinçok

Pediatrics

Spec. MD. Sadık İsmayılov

Related Videos

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91